The Prognosis Role of AST/ALT (De Ritis) Ratio in Patients with Adult Secondary Hemophagocytic Lymphohistiocytosis

Table 2

Uni- and multivariate Cox regression analyses of overall survival.

	Unadjusted		Adjusted
	HR (95% CI)		HR (95% CI)
Male	1.5 (1.1-2.0)	0.011
	1.3 (0.9-1.7)	0.065
	1.2 (0.9-1.5)	0.294
	1.4 (1.0-1.8)	0.030
	1.9 (1.2-3.0)	0.004
	1.9 (1.4-2.5)	<0.001	1.4 (1.0-1.9)	0.031
	1.1 (0.9-1.5]	0.390
	1.7 (1.3-2.2)	<0.001	1.5 (1.1-2.0)	0.008
	1.2(0.9-1.6)	0.244
Splenomegaly	1.1 (0.7-1.7)	0.651
Hepatomegaly	1.8 (1.3-2.5)	0.001	1.6 (1.1-2.2)	0.011
Lymphadenopathy	1.2 (0.9-1.5)	0.268
Hemophagocytosis	0.9 (0.6-1.3)	0.436
	1.9 (1.4-2.6)	<0.001	1.9 (1.4-2.6)	<0.001
	1.6 (1.1-2.1)	0.005
EBV infection	1.8 (1.4-2.4)	<0.001	1.5 (1.1-2.0)	0.009
MHLH	1.8 (1.3-2.4)	<0.001	1.8 (1.3-2.5)	<0.001
Chemotherapy	0.9 (0.6-1.4)	0.670	0.4 (0.3-0.7)	<0.001
De-Ritis ratio
≤1.00	1 (ref)		1 (ref)
1.01 < ratio ≤1.79	1.4 (1.0-2.0)	0.056	1.2 (0.8-1.7)	0.444
>1.80	1.8 (1.3-2.5)	0.001	1.6 (1.1-2.2)	0.013

Abbreviations: ANC: absolute neutrophil count; HB: hemoglobin; PLT: platelet; LDH: lactate dehydrogenase; ALB: albumin; TG: triglyceride; FIB: fibrinogen; sCD25: soluble interleukin-2 receptor; EBV: Epstein-Barr virus; MHLH: malignancy-associated hemophagocytic lymphohistiocytosis; De-Ritis ratio: aspartate transaminase/alanine transaminase; HR: hazards ratio; 95% CI: 95% confidence interval.